Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Levothyroxin, ATC H03AA01 für die Zeit 01.04.2026 - 31.03.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a (8) SGB V enables health insurance funds and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly carries out substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Levothyroxin, ATC H03AA01, the DAK-Gesundheit intends to conclude pharmaceutical rebate contracts with as many interested pharmaceutical companies as possible until new pharmaceutical rebate contracts come into force. A rebate contract under the authorisation model for the aforementioned active substance comes into force for the first time on 01.04.2026 and ends on 31.03.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, irrespective of this.